Posts

Posted on

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a public offering price of $24.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 shares of common stock at a public offering price of $23.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. Monte Rosa also granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Monte Rosa from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $300 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares and pre-funded warrants in the offering are to be sold by Monte Rosa. The offering is expected to close on or about January 12, 2026, subject to satisfaction of customary closing conditions.

Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering. Wedbush PacGrow and LifeSci Capital are acting as passive bookrunners for the offering.

The shares and pre-funded warrants are being offered by Monte Rosa pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on March 20, 2025 and declared effective by the SEC on March 31, 2025 (File No. 333-285942). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov.

The final prospectus supplement relating to and describing the final terms of the offering will be filed with the SEC and may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 821-7388 or by email at [email protected], TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, email at [email protected], Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at [email protected], Wedbush Securities Inc., Attn: ECM Department, 600 Montgomery Street, 29th Floor, San Francisco, CA 94111 or via email at [email protected] or LifeSci Capital LLC at 1700 Broadway, 40th Floor, New York, New York 10019, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Monte Rosa

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology.

Forward-Looking Statements 

This press release includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Monte Rosa’s expectations regarding the timing and closing of the public offering, including the satisfaction of customary closing conditions related to the offering. Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward- looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. These and the risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Monte Rosa’s most recent Annual Report on Form 10-K, as well as the most recent Quarterly Reports on Form 10-Q and any subsequent filings with the SEC. In addition, any forward-looking statements represent Monte Rosa’s views only as of as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Monte Rosa explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investors  
Andrew Funderburk
[email protected] 

Media  
Cory Tromblee, Scient PR
[email protected] 



Posted on

Mega Matrix Partners with Ihsan Dhahab to Develop an Islamic Precious Metals Real-World Asset Ecosystem

PR Newswire

SINGAPORE, Jan. 8, 2026 /PRNewswire/ — Mega Matrix Inc. (NYSE American: MPU) (the “Company”) today announced that on January 7, 2026 it entered into a memorandum of understanding (“MOU”) with Ihsan Dhahab Sdn Bhd (“Ihsan Dhahab”) to finance and operate a comprehensive precious metals special economic zone in Saudi Arabia, a Shariah‑compliant RWA gold‑backed token and stablecoin, a Shariah‑compliant RWA precious metals and bullion exchange, an Islamic digital gold bank, and other associated innovative fintech projects.

Under the MOU, the parties agreed to collaborate on a range of projects, including:

  • To develop an integrated precious metals special economic zone located in the Middle East, primarily in Saudi Arabia, Qatar or other locations, dedicated to the entire precious metals value chain, including refining, storage, trading, and manufacturing;
  • To design, structure, develop, and launch a leading Shariah-compliant, Real-World Asset (RWA) gold-backed token and stablecoin;
  • To establish and operate a leading Shariah-compliant digital exchange for the trading of precious metals, bullion, and other RWA-based financial instruments;
  • To create a leading Islamic digital bullion bank, providing Shariah-compliant financing, vaulting, logistics, and other banking services for the precious metals ecosystem; and
  • To collaboratively identify, assess, and develop other innovative fintech projects that align with the strategic objectives of the parties.

As part of the collaboration, MPU will draw on its technical experience in stablecoins and Web3 to provide advisory support for capital raising and financing, including equity investments, debt arrangements and other compliant financial instruments. MPU will also provide expertise in corporate structuring, financial modelling, capital markets strategy and international governance standards, and will contribute its technology, intellectual property and global blockchain and digital asset network to support project implementation and scalable development.

Ihsan Dhahab will act as the founders Group and promoter, leveraging their local presence and market knowledge in Saudi Arabia, Qatar and the wider region to provide strategic direction, sector expertise in Islamic finance and precious metals markets, and to lead regulatory approvals, licensing and day-to-day operations following project commencement.

Yucheng Hu, CEO of MPU, commented, “Partnering with Ihsan Dhahab that has deep local experience and resources in the Middle East to develop the precious metals RWA sector represents a measured extension of MPU’s stablecoin and its governance token DAT strategy. MPU is contributing to the development of global digital financial infrastructure while broadening its activities within the stablecoin and Web3 landscape.”

About Mega Matrix Inc.: Mega Matrix Inc. (NYSE American: MPU), a holding company headquartered in Singapore is executing its strategic digital asset treasury (“DAT”) strategy by looking to diversifying its basket of leading stablecoins and their governance tokens, and operates FlexTV, a short-video streaming platform and producer of short dramas, through Yuder Pte, Ltd., an indirect wholly owned subsidiary of the Company. For more information, please contact [email protected] or visit http://www.megamatrix.io.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements that are purely historical are forward looking statements. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose,” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees for future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, are the: ability to manage growth; ability to identify and integrate future acquisitions; ability to grow and expand our FlexTV business; ability to purchase stablecoin governance tokens, Bitcoin or Ethereum at the price that we want; ability to reinitiate the ETH staking business, ability to implement the strategic expansion into the stablecoin sector, ability to implement the new business strategy with a focus on stablecoin governance token and ability to create value; the regulatory volatility on stablecoins and governance tokens; ability to obtain additional financing in the future to fund capital expenditures and our digital asset treasury (“DAT”) reserve strategy and ability to create value; fluctuations in general economic and business conditions; costs or other factors adversely affecting the Company’s profitability; litigation involving patents, intellectual property, and other matters; potential changes in the legislative and regulatory environment; a pandemic or epidemic; the possibility that the Company may not succeed in developing its new lines of businesses due to, among other things, changes in the business environment, competition, changes in regulation, or other economic and policy factors; and the possibility that the Company’s new lines of business may be adversely affected by other economic, business, and/or competitive factors. The forward-looking statements in this press release and the Company’s future results of operations are subject to additional risks and uncertainties set forth under the heading “Risk Factors” in documents filed by the Company with the Securities and Exchange Commission (“SEC”), including the Company’s latest annual report on Form 20-F, filed with the SEC on March 28, 2025, and are based on information available to the Company on the date hereof. In addition, such risks and uncertainties include the inherent risks with investing in digital assets such as stablecoins, governance tokens, Bitcoin and/or Ethereum,  Digital asset‘s volatility; and risk of implementing a new DAT strategy focusing on digital assets. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Disclosure Channels

We announce material information about the Company and its services and for complying with our disclosure obligation under Regulation FD via the following social media channels:

 X (f/k/a Twitter):

twitter.com/MegaMatrixMPU 

Facebook:

facebook.com/megamatrixmpu 

LinkedIn:

linkedin.com/company/megamatrixmpu

The Company will also use its landing page on its corporate website (www.megamatrix.io) to host social media disclosures and/or links to/from such disclosures. The information we post through these social media channels may be deemed material. Accordingly, investors should monitor these social media channels in addition to following our website, press releases, SEC filings and public conference calls and webcasts. The social media channels that we intend to use as a means of disclosing the information described above may be updated from time to time as listed on our website.

For inquiries, please contact:  [email protected]  

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mega-matrix-partners-with-ihsan-dhahab-to-develop-an-islamic-precious-metals-real-world-asset-ecosystem-302657044.html

SOURCE Mega Matrix Inc.

Posted on

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. – VTYX

PR Newswire

NEW YORK and NEW ORLEANS, Jan. 8, 2026 /PRNewswire/ — Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ventyx Biosciences, Inc. (NasdaqGS: VTYX) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Ventyx will receive $14.00 in cash for each share of Ventyx that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-vtyx/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ventyx-biosciences-investor-alert-kahn-swick–foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-ventyx-biosciences-inc—vtyx-302656934.html

SOURCE Kahn Swick & Foti, LLC

Posted on

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

PR Newswire

NEWTOWN, Pa., Jan. 8, 2026 /PRNewswire/ — Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Ventyx Biosciences, Inc. (“Ventyx”) (NASDAQ: VTYX), resulting from allegations of providing potentially misleading business information to the investing public.

If you have information that could assist in the Ventyx Investigation or if you are a Ventyx investor who suffered a loss and would like to learn more, you can provide your information

HERE

.

You can also contact attorney Eric Lechtzin by calling 844-563-5550, ext. 1, or via email at [email protected].

THE COMPANY:

Ventyx Biosciences develops oral therapies for autoimmune, inflammatory, and neurodegenerative diseases.

THE ALLEGED WRONGDOING:

On December 2, 2025, Ventyx updated its Phase 2 trial of VTX2735 for recurrent pericarditis, announcing that topline results are now expected in Q1 2026. The CEO explained that the delay will allow the company to test a new once-daily formulation and expand the study into Canada, the EU, and the UK to accelerate Phase 3 development. On this news, Ventyx’s stock price fell $1.44 per share, or 15.35%, to close at $7.94 per share on December 2, 2025.

ABOUT EDELSON LECHTZIN LLP: Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving securities and investment fraud, our lawyers focus on class and collective litigation alleging violations of the federal antitrust laws, ERISA employee benefit plans, wage theft and unpaid overtime, consumer fraud, and dangerous and defective drugs and medical devices.


For more information, please contact:

Eric Lechtzin, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492 ext. 1
Email: [email protected]
Web:  www.edelson-law.com 

This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-ventyx-biosciences-inc-nasdaq-vtyx-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information-to-contact-the-firm-302656991.html

SOURCE Edelson Lechtzin LLP

Posted on

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Voluntary agreement will allow millions of Americans to purchase medicines at significantly discounted rates

Agreement provides Johnson & Johnson pharmaceutical products an exemption from U.S. tariffs

Company announces two new additional manufacturing facilities to be built in North Carolina and Pennsylvania; continues to deliver on $55 billion U.S. investment

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–
Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs1.

“Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives and ensuring that the United States continues to lead the world in healthcare innovation.”

Improving Access and Lowering Costs for U.S. Patients

Johnson & Johnson is working with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The Company is:

  • Participating in TrumpRx.gov, a direct to patient platform, which will allow millions of American patients to purchase medicines from Johnson & Johnson at significantly discounted rates.

  • Enabling American patients to access medicines at comparable prices to other developed countries.

  • Providing Medicaid program access at comparable prices to other developed countries.

  • Continuing to support the Administration’s efforts to ensure better recognition of the value of health care across developed markets globally.

Delivering On Our $55B U.S. Investment

Johnson & Johnson also continues to deliver on our previously announced $55 billion investment to support U.S. manufacturing, research and development, and technology investments by early 2029. In just the last 10 months, the Company has initiated billions of dollars in investment in U.S. manufacturing, which will support the Company’s goal of manufacturing the vast majority of its advanced medicines in the U.S. to meet the needs of U.S. patients.

Today, as part of the $55 billion investment, the Company is announcing two new U.S. manufacturing facilities, including a next generation cell therapy manufacturing site in Pennsylvania and a state-of-the-art drug product manufacturing facility in North Carolina.

Additionally, construction is progressing on our $2 billion state-of-the-art biologics manufacturing facility in Wilson, North Carolina, which the Company broke ground on last year. That project will create approximately 5,000 skilled manufacturing and construction jobs in the state. Johnson & Johnson is already ramping up the hiring of advanced manufacturing employees to work at the facility.

In September, the Company also secured a new 160,000+ square foot dedicated biopharmaceutical manufacturing site in Holly Springs, North Carolina. The $2 billion commitment over the next 10 years will create approximately 120 new jobs in North Carolina.

Johnson & Johnson expects to announce additional U.S. investments later this year.

About Johnson & Johnson:

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at www.jnj.com.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory actions; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

1 Specific terms of the agreement remain confidential.

Media contact:

[email protected]

Investor contact:

[email protected]

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: White House/Federal Government Public Policy/Government Health Other Health General Health Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation into New Era Energy & Digital, Inc. (NASDAQ: NUAI) and Encourages Investors with Substantial Losses to Contact the Firm

PR Newswire

NEWTOWN, Pa., Jan. 8, 2026 /PRNewswire/ — Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving New Era Energy & Digital, Inc. (“New Era”) (NASDAQ: NUAI), resulting from allegations of providing potentially misleading business information to the investing public.

If you have information that could assist in the New Era Investigation or if you are a New Era investor who suffered a loss and would like to learn more, you can provide your information

HERE

.

You can also contact attorney Eric Lechtzin by calling 844-563-5550, ext. 1, or via email at [email protected].

THE COMPANY:

New Era Energy & Digital, Inc. develops and operates digital infrastructure and integrated power assets.

THE ALLEGED WRONGDOING:

On December 12, 2025, Investing.com published a report stating that Fuzzy Panda Research had issued an analysis of New Era, accusing the company of prioritizing stock promotion over its core oil and gas operations, and alleging that CEO E. Will Gray II had a long history of failed penny-stock ventures. On this news, New Era’s stock price fell $0.25 per share, or 6.9%, to close at $3.35 on December 13, 2025.

Then, on December 29, 2025, short-seller firm Hunterbrook reported that the State of New Mexico had filed a lawsuit against New Era, its CEO, and related entities, alleging they operated a fraudulent oil-and-gas operation and shifted environmental cleanup costs to the state. The lawsuit claimed the scheme left New Mexico responsible for plugging costs associated with hundreds of abandoned wells. On this news, New Era’s stock price fell another $2.19 per share, or 48.03%, over the following two trading sessions, to close at $2.37 per share on December 29, 2025.

ABOUT EDELSON LECHTZIN LLP: Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving securities and investment fraud, our lawyers focus on class and collective litigation alleging violations of the federal antitrust laws, ERISA employee benefit plans, wage theft and unpaid overtime, consumer fraud, and dangerous and defective drugs and medical devices.


For more information, please contact:

Eric Lechtzin, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492 ext. 1
Email: [email protected]
Web: www.edelson-law.com 

This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-into-new-era-energy–digital-inc-nasdaq-nuai-and-encourages-investors-with-substantial-losses-to-contact-the-firm-302656986.html

SOURCE Edelson Lechtzin LLP

Posted on

TrueBlue Highlights Recent Board Refreshment and Strategic Initiatives Underway to Achieve Long-Term Profitable Growth

TrueBlue Highlights Recent Board Refreshment and Strategic Initiatives Underway to Achieve Long-Term Profitable Growth

Responds to Director Nominations from EHS Management

No Shareholder Action Required at This Time

TACOMA, Wash.–(BUSINESS WIRE)–
TrueBlue, Inc. (NYSE: TBI) (“TrueBlue” or the “Company”) today issued the following statement in response to the comments made by, and nominations from, EHS Management, LLC (“EHS”):

TrueBlue is executing a disciplined and decisive plan that is leading to improved financial results, and the Company is well on its way to returning to sustainable, profitable growth. Under our strategic plan, TrueBlue has strengthened performance in attractive end markets, particularly within skilled businesses, while streamlining our cost structure to deliver stronger leverage and enhanced profitability. We also continue to demonstrate digital leadership with enterprise-wide enhancements to our proprietary technology platforms driving faster, more precise and transparent workforce solutions. This reflects our ongoing commitment to improved profitability through operational efficiency, technology leverage and sustainable margin expansion.

With continued disciplined execution, TrueBlue is well-positioned to capitalize on a large, fragmented staffing market and deliver greater shareholder value as the market recovers.

The Board is committed to effective corporate governance and to positioning TrueBlue for long-term success. Over the past several years, TrueBlue has thoughtfully evolved the composition of its Board to align with the Company’s strategic priorities, enhance diversity of experience, and strengthen oversight capabilities across key areas, such as technology, workforce solutions, and operations.

The Board dedicated months to engaging with shareholders to inform its most recent refreshment process, which resulted in the appointments of William Greenblatt and William Seward, two highly qualified professionals with decades of industry experience and proven operational and commercial expertise. TrueBlue also announced that two existing directors will step down from the Board at or before the 2026 Annual Meeting of Shareholders. These appointments and planned retirements – which were endorsed by TrueBlue’s largest shareholder – reflect TrueBlue’s ongoing commitment to evolving the composition of its Board to strengthen operational oversight, accelerate growth and transformation, and incorporate shareholder feedback.

As part of this refreshment process, the Board and leadership team engaged substantively with Eric Su of EHS to articulate the changes underway. In fact, the Board made Eric Su aware of its refreshment plans, well in advance of Mr. Su publicly stating that he intended to nominate directors to the TrueBlue Board.

As part of those constructive efforts, the Board reviewed numerous candidates, including Mr. Su, and ultimately determined that William Greenblatt and William Seward are superior directors with the right skill sets to advance the Company’s strategy and enhance the value of TrueBlue. It is unfortunate that EHS is now waging a costly and disruptive proxy contest when change and momentum are already in progress under the direction of the Board.

Today, the TrueBlue Board of Directors comprises qualified professionals with deep industry, operational and financial expertise. Together, these directors bring experience and perspectives critical to executing TrueBlue’s long-term growth strategy.

The TrueBlue Board and management team are committed to serving the best interests of all our shareholders. We remain open to constructive feedback, and we will continue to take actions that drive long-term value creation for all our shareholders.

Shareholders are not required to take any action at this time. The Board will present its recommendations with respect to the election of directors in the Company’s definitive proxy statement, which will be filed with the Securities and Exchange Commission and mailed to all shareholders eligible to vote at the 2026 Annual Meeting.

Barclays is acting as financial advisor, and Sidley Austin LLP is serving as legal counsel to TrueBlue.

About TrueBlue

TrueBlue (NYSE: TBI) is a leading provider of specialized workforce solutions. As The People Company®, we put people first—advancing our mission to connect people and work while delivering smart, scalable solutions that help businesses grow and communities thrive. Since our founding, TrueBlue has connected more than 10 million people with work and served over 3 million clients across a variety of industries. Powered by proprietary, digitally enabled platforms and decades of expertise, our brands—PeopleReady, PeopleScout, Staff Management | SMX, Centerline, SIMOS, and Healthcare Staffing Professionals—provide a full spectrum of flexible staffing, workforce management, and recruitment solutions that bring precision, speed, and scale to the changing world of work. Learn more at www.trueblue.com.

Forward Looking Statements

This document contains forward-looking statements relating to our plans and expectations including, without limitation, statements regarding the future performance and operations of our business, expectations regarding stabilization in demand, and expected growth from our digital investments, all of which are subject to risks and uncertainties. Such statements are based on management’s expectations and assumptions as of the date of this release and involve many risks and uncertainties that could cause actual results to differ materially from those expressed or implied in our forward-looking statements including: (1) national and global economic conditions, which can be negatively impacted by factors such as rising interest rates, inflation, changes in government policies, political instability, epidemics and global trade uncertainty, (2) factors relating to any unsolicited offer (“Offer”) to purchase the shares of the Company, actions taken by the Company or its shareholders with respect to such an Offer, and the effects of such an Offer, or the completion or failure to complete an Offer on the Company’s business, or other developments involving such an Offer and/or shareholders or others who may disagree with the composition of the Board, our strategy, or the management of the Company; (3) our ability to maintain profit margins, (4) our ability to attract and retain clients, (5) our ability to access sufficient capital to finance our operations, including our ability to comply with covenants contained in our revolving credit facility, (6) our ability to successfully execute on business strategies and further digitalize our business model, (7) our ability to attract sufficient qualified candidates and employees to meet the needs of our clients, (8) new laws, regulations, and government incentives that could affect our operations or financial results, (9) any reduction or change in tax credits we utilize, including the Work Opportunity Tax Credit, (10) our ability to successfully integrate acquired businesses, and (11) the timing and amount of common stock repurchases, if any, which will be determined at management’s discretion and depend upon several factors, including market and business conditions, the trading price of our common stock and the nature of other investment opportunities. Other information regarding factors that could affect our results is included in our Securities and Exchange Commission (“SEC”) filings, including the Company’s most recent reports on Forms 10-K and 10-Q, copies of which may be obtained by visiting our website at www.trueblue.com under the Investor Relations section or the SEC’s website at www.sec.gov. We assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. Any other references to future financial estimates are included for informational purposes only and subject to risk factors discussed in our most recent filings with the SEC.

Important Information for Investors and Shareholders

The Company intends to file a proxy statement on Schedule 14A, an accompanying BLUE proxy card, and other relevant documents with the SEC in connection with the solicitation of proxies from the Company’s shareholders for the Company’s 2026 annual meeting of shareholders. THE COMPANY’S SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE COMPANY’S DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), THE ACCOMPANYING BLUE PROXY CARD, AND ANY OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Shareholders may obtain a free copy of the definitive proxy statement, an accompanying BLUE proxy card, any amendments or supplements to the proxy statement, and other documents that the Company files with the SEC at no charge from the SEC’s website at www.sec.gov. Copies will also be available at no charge by clicking the “All SEC Filings” link in the “Investor Relations” section of the Company’s website at https://investor.trueblue.com/sec-filings/all-sec-filings.

Participants in the Solicitation

The Company, its independent directors and certain of its executive officers are deemed to be “participants” (as defined in Schedule 14A under the Exchange Act of 1934, as amended) in the solicitation of proxies from the Company’s shareholders in connection with matters to be considered at the Company’s 2026 annual meeting of shareholders. Information about the names of the Company’s directors and officers, and certain other individuals and their respective interests in the Company by security holdings or otherwise, and their respective compensation, is set forth in the sections entitled “Director Biographies,” “Compensation of Directors,” “Compensation Discussion and Analysis” and “Security Ownership of Certain Beneficial Owners and Management” of the Company’s Proxy Statement on Schedule 14A in connection with the 2025 annual meeting of shareholders, filed with the SEC on April 4, 2025 (available here) and the Company’s Annual Report on Form 10-K filed with the SEC on February 19, 2025 (available here). Supplemental information regarding the participants’ holdings of the Company’s securities can be found at no charge in SEC filings on Statements of Change in Ownership on Form 4 filed with the SEC on October 6, 2025 and October 7, 2025 for Taryn R. Owen (available here and here), and on November 4, 2025 for Carl R. Schweihs (available here). Such filings are also available on the Company’s website at https://investor.trueblue.com/sec-filings/all-sec-filings. Any subsequent updates following the date hereof to the information regarding the identity of potential participants and their direct or indirect interests, by security holdings or otherwise, will be set forth in the Company’s proxy statement on Schedule 14A and other materials to be filed with the SEC in connection with the 2026 annual meeting of shareholders, if and when they become available. These documents will be available free of charge as described above.

Investor Relations

[email protected]

Media

Collected Strategies

Dan Moore and Jack Kelleher

[email protected]

KEYWORDS: Washington United States North America

INDUSTRY KEYWORDS: Professional Services Business Human Resources

MEDIA:

Logo
Logo
Posted on

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm

PR Newswire

NEWTOWN, Pa., Jan. 8, 2026 /PRNewswire/ — Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Anavex Life Sciences Corp. (“Anavex”) (NASDAQ: AVXL), resulting from allegations of providing potentially misleading business information to the investing public.

If you have information that could assist in the Anavex Investigation or if you are an Anavex investor who suffered a loss and would like to learn more, you can provide your information

HERE

.

You can also contact attorney Eric Lechtzin by calling 844-563-5550, ext. 1, or via email at [email protected].

THE COMPANY:

Anavex Life Sciences Corp. is a clinical-stage biotech developing targeted therapies for neurodegenerative and CNS disorders like Alzheimer’s and Parkinson’s.

THE ALLEGED WRONGDOING:

On November 14, 2025, Anavex announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency delivered an unfavorable preliminary opinion on its marketing application for blarcamesine after an oral review. On this news, Anavex’s stock price fell $2.05 per share, or 35.94%, to close at $3.65 per share on November 14, 2025.

ABOUT EDELSON LECHTZIN LLP: Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving securities and investment fraud, our lawyers focus on class and collective litigation alleging violations of the federal antitrust laws, ERISA employee benefit plans, wage theft and unpaid overtime, consumer fraud, and dangerous and defective drugs and medical devices.

For more information, please contact:

Eric Lechtzin, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492 or 215-867-2399 ext. 1
Email: [email protected]
Web: www.edelson-law.com 

This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investigation-alert-edelson-lechtzin-llp-announces-an-investigation-of-anavex-life-sciences-corp-nasdaq-avxl-and-encourages-investors-with-substantial-losses-contact-the-firm-302656983.html

SOURCE Edelson Lechtzin LLP

Posted on

Fluor Achieves Mechanical Completion on BASF’s New Verbund Site Project in South China

Fluor Achieves Mechanical Completion on BASF’s New Verbund Site Project in South China

IRVING, Texas–(BUSINESS WIRE)–Fluor Corporation (NYSE: FLR) announced today that it has achieved mechanical completion on BASF’s Zhanjiang Verbund project in China – BASF’s largest investment to date. The achievement was delivered with an outstanding safety record of more than 75 million work hours without a Lost Time Injury.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108471342/en/

BASF’s Zhanjiang Verbund site in China.

BASF’s Zhanjiang Verbund site in China.

“This milestone highlights Fluor’s commitment to safe and quality execution on complex, world‑class chemical projects,” said Pierre Bechelany, Fluor’s Business Group President of Energy Solutions. “I commend our teams and partners for their disciplined delivery and exceptional performance. We are honored to support BASF’s strategic growth in China with this new Verbund site project.”

Fluor provided critical engineering, procurement and construction support for BASF’s integrated operations, including an EOEG process unit, 220kV substation, steam plant, water treatment systems, seawater intake, distributed cooling towers, wastewater treatment and waste handling units, container yard, automated warehouses, and site‑wide piping and logistics infrastructure.

“Delivering the project is a tremendous achievement and a proud moment for our team,” said Charles McManemin, President of Fluor’s Chemicals business. “Our long-standing partnership with BASF is built on trust, technical excellence and a shared commitment to safe, reliable project execution. This milestone reflects years of collaboration, innovation and disciplined performance across all phases of work.”

Fluor began early site work in late 2021 and, at peak, approximately 13,000 workers were engaged across multiple construction areas.

Once fully operational, the Zhanjiang Verbund Site will be BASF’s third largest Verbund site worldwide after Ludwigshafen and Antwerp. The site will serve as a model for sustainable production in China and globally, and mainly supply customers in the Chinese market, the largest and fastest growing chemical market in the world.

About Fluor Corporation

Fluor Corporation (NYSE: FLR) is building a better world by applying world-class expertise to solve its clients’ greatest challenges. Fluor’s nearly 27,000 employees provide professional and technical solutions that deliver safe, well-executed, capital-efficient projects to clients around the world. Fluor had revenue of $16.3 billion in 2024 and is ranked 257 among the Fortune 500 companies. With headquarters in Irving, Texas, Fluor has provided engineering, procurement, construction and maintenance services for more than a century. For more information, please visit www.fluor.com or follow Fluor on Facebook, Instagram, LinkedIn, X and YouTube.

#EnergySolutions

Brett Turner

Media Relations

864.281.6976

Jason Landkamer

Investor Relations

469.398.7222

KEYWORDS: Texas China United States North America Asia Pacific

INDUSTRY KEYWORDS: Engineering Chemicals/Plastics Manufacturing

MEDIA:

Photo
Photo
BASF’s Zhanjiang Verbund site in China.
Logo
Logo
Posted on

Murphy Oil Corporation Announces Pricing of $500 Million of 6.500% Senior Notes Due 2034

Murphy Oil Corporation Announces Pricing of $500 Million of 6.500% Senior Notes Due 2034

HOUSTON–(BUSINESS WIRE)–
Murphy Oil Corporation (the “Company”) (NYSE: MUR) announced today that it has priced an offering of $500 million of 6.500% Senior Notes due 2034 pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission (“SEC”).

The Company expects to close the offering on January 23, 2026, subject to customary closing conditions, and expects to use the net proceeds from the offering, (i) to fund the redemption in full of its 5.875% notes due 2027 and its 6.375% notes due 2028 (together, the “Existing Notes”), together with the payment of related premiums, fees and expenses in connection with the foregoing, (ii) to repay its outstanding borrowing under its revolving credit facility, (iii) to cover transaction related fees and expenses and (iv) for general corporate purposes.

BofA Securities is acting as physical book-running manager for the offering. The offering is being made under an automatic shelf registration statement on Form S-3 (Registration No. 333-282655) filed by the Company with the SEC and only by means of a prospectus supplement and accompanying prospectus. An investor may obtain free copies of the prospectus supplement and accompanying prospectus related to the offering by visiting EDGAR on the SEC website, www.sec.gov, or by contacting:

BofA Securities

NC1-004-03-43

200 North College Street, 3rd Floor

Charlotte, NC 28255-0001

Attn: Prospectus Department

Email: [email protected]

This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In addition, this news release does not constitute a notice of redemption of the Existing Notes.

ABOUT MURPHY OIL CORPORATION

Murphy Oil Corporation is an independent oil and natural gas company with a multi-basin onshore and offshore portfolio and significant exploration opportunities. The company has more than a century-long history of demonstrating strong execution and innovative, full-cycle development capabilities with a focus on value creation that drives shareholder returns. Murphy’s foresight and financial discipline, along with its culture of adaptability and accountability, will allow the company to continue its outstanding legacy and exceptional reputation. The company’s current operations include extensive inventory located onshore in the Eagle Ford Shale, Tupper Montney and Kaybob Duvernay, as well as offshore in the Gulf of America and Canada. Murphy also strives to create long-term shareholder value through offshore exploration and development in the Gulf of America, Vietnam and Côte d’Ivoire.

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified through the inclusion of words such as “aim”, “anticipate”, “believe”, “drive”, “estimate”, “expect”, “expressed confidence”, “forecast”, “future”, “goal”, “guidance”, “intend”, “may”, “objective”, “outlook”, “plan”, “position”, “potential”, “project”, “seek”, “should”, “strategy”, “target”, “will” or variations of such words and other similar expressions. These statements, which express management’s current views concerning future events, results and plans, are subject to inherent risks, uncertainties and assumptions (many of which are beyond our control) and are not guarantees of performance. In particular, statements, express or implied, concerning the Company’s future operating results or activities and returns or the Company’s ability and decisions to replace or increase reserves, increase production, generate returns and rates of return, replace or increase drilling locations, reduce or otherwise control operating costs and expenditures, generate cash flows, pay down or refinance indebtedness, achieve, reach or otherwise meet initiatives, plans, goals, ambitions or targets with respect to emissions, safety matters or other ESG (environmental/social/governance) matters, make capital expenditures or pay and/or increase dividends or make share repurchases and other capital allocation decisions are forward-looking statements.Factors that could cause one or more of these future events, results or plans not to occur as implied by any forward-looking statement, which consequently could cause actual results or activities to differ materially from the expectations expressed or implied by such forward-looking statements, include, but are not limited to: macro conditions in the oil and natural gas industry, including supply/demand levels, actions taken by major oil exporters and the resulting impacts on commodity prices; geopolitical concerns; increased volatility or deterioration in the success rate of our exploration programs or in our ability to maintain production rates and replace reserves; reduced customer demand for our products due to environmental, regulatory, technological or other reasons; adverse foreign exchange movements; political and regulatory instability in the markets where we do business; the impact on our operations or market of health pandemics such as COVID-19 and related government responses; other natural hazards impacting our operations or markets; any other deterioration in our business, markets or prospects; any failure to obtain necessary regulatory approvals; any inability to service or refinance our outstanding debt or to access debt markets at acceptable prices; or adverse developments in the U.S. or global capital markets, credit markets, banking system or economies in general, including inflation, trade policies, tariffs and other trade restrictions. For further discussion of factors that could cause one or more of these future events or results not to occur as implied by any forward-looking statement, see “Risk Factors” in our most recent Annual Report on Form 10-K filed with the SEC and any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K that we file, available from the SEC’s website. Murphy Oil Corporation undertakes no duty to publicly update or revise any forward-looking statements.

Investor Contacts:

[email protected]

Atif Riaz, 281-675-9358

Beth Heller, 281-675-9363

Dimitra Vlachou, 713-502-7054

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Oil/Gas Energy

MEDIA:

Logo
Logo